12月5日，中国证监会发布《上市公司监督管理条例（公开征求意见稿）》（以下简称"《条例》"），向社会公开征求意见。这意味着中国将 迎来首部专门的上市公司监管行政法规。《条例》从完善上市公司治理要求，进一步强化信息披露监管，规范并购重组，加强投资者保护，严 厉打击违法违规行为等方面进一步健全上市公司监管法规体系，推动提高上市公司质量。 而《条例》只是证监会印发的19件2025年度立法工作计划中的一件，立法重心就是加强资本市场重点领域监管，维护市场平稳健康发展，切实 保护广大中小投资者合法权益。 证监会构建的立体监管体系与 "长牙带刺"的监管实践，是资本市场法治化、规范化发展的核心支撑，既筑牢了风险防线，也为市场高质量发 展夯实了基础。而从ST立方（300344.SZ）财务造假案的"首恶必追、帮凶必惩"，到何某儒操纵市场案的亿元级罚单，一系列典型案例的查处 与新规的落地，勾勒出2025年资本市场监管革新的清晰脉络。 "十五五"时期是资本市场迈向高质量发展的关键阶段，唯有让监管"长牙带刺"，将中小投资者保护融入监管全链条，才能筑牢市场根基，激发 资本活力，为经济高质量发展注入持久动能。 李恒春/文 监管"长牙带刺" ...

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

浙江维康药业股份有限公司 关于非独立董事辞职暨选举职工代表董事及补选董 事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2025-050 三、关于补选董事会专门委员会委员情况 2025 年 12 月 10 日，公司召开第四届董事会第九次会议，审议通过了《关 于补选公司第四届董事会专门委员会委员的议案》，同意补选华杰女士为公司第 四届董事会战略决策委员会委员、提名委员会委员，任期自本次董事会审议通过 之日起至公司第四届董事会任期届满之日止。 四、备查文件 1、浙江维康药业股份有限公司第四届董事会第九次会议决议。 一、关于非独立董事辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于近日收到公司非 独立董事兼副总经理孔晓霞女士的书面辞职报告。因公司治理结构调整，孔晓霞 女士申请辞去公司第四届董事会非独立董事职务，同时辞去董事会战略决策委员 会委员、提名委员会委员职务，原定任职日期至 2027 年 5 月 19 日。辞去上述职 务后仍担任公司副总经理职务。孔晓霞女士的辞职未导 ...

浙江天册律师事务所 关于 浙江维康药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江维康药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 编号：TCYJS2025H2071 号 致：浙江维康药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江维康药业股份有限公司 （以下简称"维康药业"或"公司"）的委托，指派本所律师参加公司 2025 年第 一次临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会规 则》（以下简称"《股东会规则》"）等法律、法规和有关规范性文件，以及《浙 江维康药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本 法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员 的资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议 所审议 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-048 浙江维康药业股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间 （1）现场会议时间：2025年12月10日（星期三）下午14:00 （2）网络投票时间：2025年12月10日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为2025年12月10日9:15—9:25，9:30—11:30和13:00—15:00；通 过深圳证券交易所互联网投票系统进行投票的具体时间为2025年12月10日9:15— 15:00。 2、召开地点：浙江省丽水经济开发区遂松路2号研发大楼二楼会议室。 3、召开方式：现场投票与网络投票相结合的方式。 4、股东大会的召集人：公司董事会。 5、主持人：董事长刘洋先生。 6、本次股东大会的召集、召开符合《中华人民共和国公司法》、《上市公司 股东大会规则》、《深 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-049 二、董事会会议审议情况 浙江维康药业股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第四届董事会第九次会议 于 2025 年 12 月 10 日在浙江省丽水经济开发区遂松路 2 号二楼会议室以现场方 式召开。董事会根据《公司章程》之规定，经全体董事同意豁免会议通知时间要 求，现场发出会议通知。本次会议由董事长刘洋先生主持，公司应出席董事 7 人，实际出席董事 7 人。本次董事会会议的召集、召开和表决程序符合有关法律、 法规、部门规章、规范性文件和《公司章程》的规定，决议内容合法有效。 2、审议通过《关于选举第四届董事会审计委员会成员及推选召集人的议案》 3、审议通过《关于补选公司第四届董事会专门委员会委员的议案》 1、《关于选举代表公司执行公司事务的董事的议案》 董事会同意选举刘洋先生为代表公司执行公司事务的董事，并担任公司法定 代表人，任期自本次董事会审议通过之日起至第四届董 ...

Market Overview - The traditional Chinese medicine sector experienced a decline of 0.28% on December 8, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Xinguang Pharmaceutical (300519) with a closing price of 17.34, up 3.96% and a trading volume of 131,800 shares, totaling 229 million yuan [1] - Kanghui Co., Ltd. (603139) closed at 22.35, up 2.48% with a trading volume of 20,300 shares, totaling 45.04 million yuan [1] - Conversely, Weikang Pharmaceutical (300878) saw a significant decline of 8.00%, closing at 22.66 with a trading volume of 110,800 shares, totaling 251 million yuan [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 723 million yuan from institutional investors, while retail investors saw a net inflow of 469 million yuan [2] - The capital flow for specific stocks showed: - Yunnan Baiyao (000538) had a net inflow of 26.56 million yuan from institutional investors, while retail investors had a net outflow of 6,450 yuan [3] - Kang Enbei (600572) reported a net inflow of 21.85 million yuan from institutional investors, with a net outflow of 1.92 million yuan from retail investors [3]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

此前，天健所为维康药业2024年度财务报表出具了保留意见审计报告，涉及两项关键事项：一是实际控 制人过去占用公司资金，导致前期财务报表多计长期资产、少计其他应收款，虽已进行差错更正，但审 计机构无法获取完整资料核实金额准确性；二是公司于2024年12月因涉嫌信息披露违法违规被证监会立 案调查，截至审计报告日尚无结论，影响难以评估。 南方财经11月25日电，维康药业(300878.SZ)11月24日公告，拟将2025年度审计机构从天健会计师事务 所（特殊普通合伙）变更为北京中天恒会计师事务所（特殊普通合伙），原因为天健所已连续八年提供 服务，公司为保障审计独立性和客观性，适应未来发展需要而作出调整。 ...